Brief Overview
Hyphens Pharma International reported 1H26 results that met expectations, with revenue and adjusted profit after tax and minority interests (adj.PATMI) reaching 48% and 42% of full-year forecasts respectively. Revenue remained largely flat at S$89.1mn, whilst adj.PATMI declined 11% year-on-year due to increased distribution costs. The company is strategically building its product portfolio breadth and scale, though this requires higher upfront investments across multiple areas.
Investment Positives
The standout positive development was the achievement of record gross margins. Gross profit margin improved by 2.8 percentage points to reach a record 42.3%, driving gross profit up 6.6% to S$37.6mn. This margin expansion was supported by the company’s strategic focus on higher-margin products, with prescription drugs under speciality pharma representing the highest-margin segment.
The margin improvement also reflects the discontinuation of lower-margin products such as Physiolac, demonstrating management’s commitment to portfolio optimisation. Key growth products driving the business forward include Cerapro MED for atopic dermatitis, Winlevi for anti-acne treatment, Ceradan for skin repair, and D-Cure vitamin D supplement.
From a balance sheet perspective, Hyphens maintains a strong financial position with net cash of S$23mn, providing flexibility for continued investment and growth initiatives.
Investment Negatives
The primary headwind facing the company is rising operating expenses, which climbed 8% to S$30mn, representing an increase of S$2.2mn. This increase effectively offset the S$2.3mn gain in gross profit, highlighting the pressure on operating margins.
The expense increases were driven by additional investments in marketing, which rose by S$1.1mn, and staff costs, which increased by S$1mn. These higher advertising and employee expenses pulled down operating profit despite the improved gross margins.
Outlook
Hyphens is positioned for stronger second-half earnings, with the company continuing to build the breadth and scale of its product offerings. The strategic investments in employee, marketing and research costs are expected to support longer-term growth prospects.
Recommendation & Target Price
Phillip Securities Research maintains a BUY recommendation on Hyphens Pharma International with a raised target price of S$0.46, up from the previous target after lowering DCF risk assumptions. The stock trades at an attractive valuation of 9x price-to-earnings ratio.
Frequently Asked Questions
Q: What were the key financial highlights for Hyphens Pharma's 1H26 results?
A: Revenue was largely flat at S$89.1mn, whilst adj.PATMI declined 11% year-on-year. However, gross margins expanded by almost 3 percentage points to a record 42.3%.
Q: Which products are driving growth for the company?
A: Key growth products include Cerapro MED for atopic dermatitis, Winlevi for anti-acne treatment, Ceradan for skin repair, and D-Cure vitamin D supplement.
Q: What caused the decline in adjusted profit?
A: Higher distribution costs driven by increased promotional expenses (S$1.1mn) and staff costs (S$1mn) offset the gross profit gains from improved margins.
Q: Why did gross margins improve so significantly?
A: The focus on higher-margin products and discontinuation of lower-margin products such as Physiolac supported the 2.8 percentage point margin expansion.
Q: What is the company's financial position?
A: Hyphens maintains a strong balance sheet with net cash of S$23mn and trades at an attractive 9x price-to-earnings ratio.
Q: What is driving the increase in operating expenses?
A: Operating expenses rose 8% to S$30mn, primarily due to additional investments in marketing (S$1.1mn increase) and staff costs (S$1mn increase).
Q: What is the investment outlook for the company?
A: Phillip Securities Research expects stronger 2H26 earnings as the company continues building its product platform, though this requires ongoing upfront investments.
Q: What is the analyst's recommendation and target price?
A: Phillip Securities Research maintains a BUY recommendation with a raised target price of S$0.46, up from the previous target after lowering DCF risk assumptions.
This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst.
Disclaimer
These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.
Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance.
Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries.
The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.
Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.
This advertisement has not been reviewed by the Monetary Authority of Singapore.
